{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Tumor+%28Phase+I%29&page=15",
    "query": {
      "condition": "Solid Tumor (Phase I)",
      "page": 15
    },
    "page_size": 10
  },
  "pagination": {
    "page": 15,
    "page_size": 10,
    "total_count": 3263,
    "total_pages": 327,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Tumor+%28Phase+I%29&page=16&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Tumor+%28Phase+I%29&page=14&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T10:29:31.105Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00004144",
      "title": "Bryostatin 1 Plus Gemcitabine in Treating Patients With Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "bryostatin 1",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Barbara Ann Karmanos Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2000-05",
      "completion_date": "2006-12",
      "has_results": false,
      "last_update_posted_date": "2014-04-24",
      "last_synced_at": "2026-10-19T10:29:31.105Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004144"
    },
    {
      "nct_id": "NCT01654965",
      "title": "Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pegfilgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Tivantinib",
          "type": "DRUG"
        },
        {
          "name": "Topotecan Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2012-07-24",
      "completion_date": "2018-03-29",
      "has_results": false,
      "last_update_posted_date": "2018-04-03",
      "last_synced_at": "2026-10-19T10:29:31.105Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "South Pasadena",
          "state": "California"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01654965"
    },
    {
      "nct_id": "NCT04511845",
      "title": "A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locally Advanced or Metastatic Solid Tumors"
      ],
      "interventions": [
        {
          "name": "SPYK04",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Chugai Pharmaceutical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2020-09-10",
      "completion_date": "2026-06-18",
      "has_results": false,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-10-19T10:29:31.105Z",
      "location_count": 9,
      "location_summary": "Tucson, Arizona • Lone Tree, Colorado • Minneapolis, Minnesota + 6 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Lone Tree",
          "state": "Colorado"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04511845"
    },
    {
      "nct_id": "NCT01445522",
      "title": "ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "ABT-888",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "110 Years",
        "sex": "ALL",
        "summary": "18 Years to 110 Years"
      },
      "enrollment_count": 35,
      "start_date": "2008-12-03",
      "completion_date": "2012-07-03",
      "has_results": false,
      "last_update_posted_date": "2019-12-17",
      "last_synced_at": "2026-10-19T10:29:31.105Z",
      "location_count": 2,
      "location_summary": "Duarte, California • Bethesda, Maryland",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01445522"
    },
    {
      "nct_id": "NCT03234712",
      "title": "A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors Cancer"
      ],
      "interventions": [
        {
          "name": "ABBV-321",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2017-10-10",
      "completion_date": "2021-04-14",
      "has_results": false,
      "last_update_posted_date": "2021-05-06",
      "last_synced_at": "2026-10-19T10:29:31.105Z",
      "location_count": 14,
      "location_summary": "Springdale, Arkansas • Los Angeles, California • Sacramento, California + 10 more",
      "locations": [
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03234712"
    },
    {
      "nct_id": "NCT04460456",
      "title": "A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2 Positive Solid Tumors"
      ],
      "interventions": [
        {
          "name": "SBT6050",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Silverback Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2020-07-27",
      "completion_date": "2022-12",
      "has_results": false,
      "last_update_posted_date": "2022-06-30",
      "last_synced_at": "2026-10-19T10:29:31.105Z",
      "location_count": 6,
      "location_summary": "Boston, Massachusetts • Durham, North Carolina • Pittsburgh, Pennsylvania + 3 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04460456"
    },
    {
      "nct_id": "NCT01778439",
      "title": "A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed or Refractory Solid Tumors"
      ],
      "interventions": [
        {
          "name": "OMP-52M51",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OncoMed Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 48,
      "start_date": "2013-02",
      "completion_date": "2016-07",
      "has_results": false,
      "last_update_posted_date": "2020-08-11",
      "last_synced_at": "2026-10-19T10:29:31.105Z",
      "location_count": 6,
      "location_summary": "San Francisco, California • Aurora, Colorado • Detroit, Michigan + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01778439"
    },
    {
      "nct_id": "NCT03665129",
      "title": "IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "IPH5401 and Durvalumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Innate Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 73,
      "start_date": "2018-09-07",
      "completion_date": "2021-02-24",
      "has_results": false,
      "last_update_posted_date": "2022-01-27",
      "last_synced_at": "2026-10-19T10:29:31.105Z",
      "location_count": 5,
      "location_summary": "Louisville, Kentucky • Saint Louis Park, Minnesota • New York, New York + 2 more",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Saint Louis Park",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03665129"
    },
    {
      "nct_id": "NCT00923728",
      "title": "A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Refractory Solid Tumors"
      ],
      "interventions": [
        {
          "name": "AVN944",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2009-04",
      "completion_date": "2010-03",
      "has_results": false,
      "last_update_posted_date": "2014-01-10",
      "last_synced_at": "2026-10-19T10:29:31.105Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00923728"
    },
    {
      "nct_id": "NCT00003956",
      "title": "Combination Chemotherapy in Treating Patients With Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "leucovorin calcium",
          "type": "DRUG"
        },
        {
          "name": "lonafarnib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "1999-04",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2013-04-04",
      "last_synced_at": "2026-10-19T10:29:31.105Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003956"
    }
  ]
}